Skip to main content

Dr. Santosh Kumar, MD

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2007
Medicare patients seen, 2024
572

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    NY license 257526

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
572
Services billed
35,096
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml15,63079
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count1,275337
Insertion of needle into vein for collection of blood sample1,268339
Blood test, comprehensive group of blood chemicals1,076309
Established patient office or other outpatient visit, 30-39 minutes585292
Gammaglobulin (immune system protein) measurement37378
Established patient office or other outpatient visit, 20-29 minutes231211
Ferritin (blood protein) level218129
Established patient office or other outpatient visit, 40-54 minutes217114
Iron binding capacity207125

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 38 payments worth $20,924 in total to this clinician.

By company
AstraZeneca Pharmaceuticals LP$6,875
Exelixis Inc.$3,948
Pfizer Inc.$3,712
Geron Corporation$3,551
Novartis Pharmaceuticals Corporation$1,463
Daiichi Sankyo Inc.$650
Gilead Sciences, Inc.$450
Cardinal Health 110 LLC$275
By type
Consulting Fee$11,793
Compensation for services other than consulting (speaking, faculty)$3,500
Travel and Lodging$2,688
Honoraria$1,975
Food and Beverage$969

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 13, 2025Pfizer Inc.
Jan 13, 2025
Compensation for services other than consulting (speaking, faculty)
TIVDAK · ONCOLOGY
$3,500
Jul 1, 2025AstraZeneca Pharmaceuticals LP
Jul 1, 2025
Consulting Fee
IMFINZI · Oncology
$2,475
Dec 4, 2025Geron Corporation
Dec 4, 2025
Consulting Fee
IMETELSTAT · HEMATOLOGY
$2,080
Jun 26, 2025Exelixis Inc.
Jun 26, 2025
Honoraria
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,975
Jul 1, 2025AstraZeneca Pharmaceuticals LP
Jul 1, 2025
Consulting Fee
IMFINZI · Oncology
$1,925
Dec 3, 2025Novartis Pharmaceuticals Corporation
Dec 3, 2025
Consulting Fee
SCEMBLIX · Oncology
$1,463
Nov 6, 2025AstraZeneca Pharmaceuticals LP
Nov 6, 2025
Consulting Fee
IMFINZI · Oncology
$1,375
Jun 18, 2025AstraZeneca Pharmaceuticals LP
Jun 18, 2025
Consulting Fee
IMFINZI · Oncology
$1,100
Jun 21, 2025Exelixis Inc.
Jun 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$717
Apr 10, 2025Daiichi Sankyo Inc.
Apr 10, 2025
Consulting Fee
Vanflyta · ONCOLOGY
$650
All 18 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 4, 2025Geron Corporation
Dec 4, 2025
Consulting Fee
IMETELSTAT · HEMATOLOGY
$2,080
Dec 4, 2025Geron Corporation
Dec 4, 2025
Travel and Lodging
IMETELSTAT · HEMATOLOGY · travel to BOSTON, MA
$405
Dec 4, 2025Geron Corporation
Dec 4, 2025
Travel and Lodging
IMETELSTAT · HEMATOLOGY · travel to BOSTON, MA
$9.32
Dec 3, 2025Novartis Pharmaceuticals Corporation
Dec 3, 2025
Consulting Fee
SCEMBLIX · Oncology
$1,463
Nov 8, 2025Geron Corporation
Nov 8, 2025
Travel and Lodging
IMETELSTAT · HEMATOLOGY · travel to BOSTON, MA
$650
Nov 6, 2025AstraZeneca Pharmaceuticals LP
Nov 6, 2025
Consulting Fee
IMFINZI · Oncology
$1,375
Jul 1, 2025AstraZeneca Pharmaceuticals LP
Jul 1, 2025
Consulting Fee
IMFINZI · Oncology
$2,475
Jul 1, 2025AstraZeneca Pharmaceuticals LP
Jul 1, 2025
Consulting Fee
IMFINZI · Oncology
$1,925
Jun 26, 2025Exelixis Inc.
Jun 26, 2025
Honoraria
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid
$1,975
Jun 21, 2025Exelixis Inc.
Jun 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC · in-kind
$717
Jun 21, 2025Exelixis Inc.
Jun 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC
$532
Jun 21, 2025Exelixis Inc.
Jun 21, 2025
Travel and Lodging
CABOMETYX · Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid · travel to Washington, DC
$163
Jun 18, 2025AstraZeneca Pharmaceuticals LP
Jun 18, 2025
Consulting Fee
IMFINZI · Oncology
$1,100
Apr 10, 2025Daiichi Sankyo Inc.
Apr 10, 2025
Consulting Fee
Vanflyta · ONCOLOGY
$650
Apr 3, 2025Gilead Sciences, Inc.
Apr 3, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4147065;VEM US;10716362
$450
Jan 17, 2025Pfizer Inc.
Jan 17, 2025
Travel and Lodging
TIVDAK · ONCOLOGY · travel to SCOTTSDALE, AZ · in-kind
$212
Jan 13, 2025Pfizer Inc.
Jan 13, 2025
Compensation for services other than consulting (speaking, faculty)
TIVDAK · ONCOLOGY
$3,500
Jan 9, 2025Cardinal Health 110 LLC
Jan 9, 2025
Consulting Fee$275

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 3 industry-funded studies in 2025, from 1 companies. The companies reported $136,159 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarci…
    Merck Sharp & Dohme LLC
  • A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-…
    Merck Sharp & Dohme LLC
  • A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Ad…
    Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in East Syracuse

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 3, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1255530911. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.